Antiviral drug. It has an inhibitory effect on herpes simplex virus, varicella zoster virus, cytomegalovirus, etc. in vitro. After entering the cells infected by herpes virus, this product competes with deoxynucleoside for viral thymidine kinase or cell kinase, and the drug is phosphorylated into activated acyclovir triphosphate, and then inhibits viral replication in two ways: ① Interfering with viral DNA polymerase and inhibiting viral replication; ② Under the action of DNA polymerase, it binds to the growing DNA chain, causing the extension of the DNA chain to be interrupted. This product has a special affinity for viruses, but has low toxicity to mammalian host cells.

This product is a mucus regulator and a potent cysteine expectorant. It mainly affects the secretion of bronchial glands at the cellular level, increasing the secretion of low-viscosity salivary mucin and reducing the production of high-viscosity fucoxanthin, thereby reducing the viscosity of sputum and making it easier to cough up.

This product is a mucus regulator and a potent cysteine expectorant. It mainly affects the secretion of bronchial glands at the cellular level, increasing the secretion of low-viscosity salivary mucin and reducing the production of high-viscosity fucoxanthin, thereby reducing the viscosity of sputum and making it easier to cough up.

It reduces the whole blood viscosity, whole blood reduced viscosity, plasma viscosity, and hematocrit of rats with blood stasis model; inhibits ADP-induced platelet aggregation in rats; prolongs the thrombosis time of rats induced by electrical stimulation; has a certain inhibitory effect on the cerebral vascular permeability of rats with experimental incomplete cerebral ischemia model induced by ligation of bilateral common carotid arteries, improves the neurological symptoms of rats with focal cerebral ischemia model induced by middle cerebral artery occlusion, and reduces the scope of cerebral infarction.

It reduces the whole blood viscosity, whole blood reduced viscosity, plasma viscosity, and hematocrit of rats with blood stasis model; inhibits ADP-induced platelet aggregation in rats; prolongs the thrombosis time of rats induced by electrical stimulation; has a certain inhibitory effect on the cerebral vascular permeability of rats with experimental incomplete cerebral ischemia model induced by ligation of bilateral common carotid arteries, improves the neurological symptoms of rats with focal cerebral ischemia model induced by middle cerebral artery occlusion, and reduces the scope of cerebral infarction.

It reduces the whole blood viscosity, whole blood reduced viscosity, plasma viscosity, and hematocrit of rats with blood stasis model; inhibits ADP-induced platelet aggregation in rats; prolongs the thrombosis time of rats induced by electrical stimulation; has a certain inhibitory effect on the cerebral vascular permeability of rats with experimental incomplete cerebral ischemia model induced by ligation of bilateral common carotid arteries, improves the neurological symptoms of rats with focal cerebral ischemia model induced by middle cerebral artery occlusion, and reduces the scope of cerebral infarction.

It reduces the whole blood viscosity, whole blood reduced viscosity, plasma viscosity, and hematocrit of rats with blood stasis model; inhibits ADP-induced platelet aggregation in rats; prolongs the thrombosis time of rats induced by electrical stimulation; has a certain inhibitory effect on the cerebral vascular permeability of rats with experimental incomplete cerebral ischemia model induced by ligation of bilateral common carotid arteries, improves the neurological symptoms of rats with focal cerebral ischemia model induced by middle cerebral artery occlusion, and reduces the scope of cerebral infarction.

It reduces the whole blood viscosity, whole blood reduced viscosity, plasma viscosity, and hematocrit of rats with blood stasis model; inhibits ADP-induced platelet aggregation in rats; prolongs the thrombosis time of rats induced by electrical stimulation; has a certain inhibitory effect on the cerebral vascular permeability of rats with experimental incomplete cerebral ischemia model induced by ligation of bilateral common carotid arteries, improves the neurological symptoms of rats with focal cerebral ischemia model induced by middle cerebral artery occlusion, and reduces the scope of cerebral infarction.